Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of April 15, 2025, Merus (MRUS) has a market cap of $2.99 billion USD. According to our data, Merus is ranked No.3351 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Apr 15, 2025 | $2.99 B |
3.72%
|
| Dec 31, 2024 | $2.88 B |
52.91%
|
| Dec 29, 2023 | $1.88 B |
77.76%
|
| Dec 30, 2022 | $1.06 B |
-51.35%
|
| Dec 31, 2021 | $2.18 B |
81.40%
|
| Dec 31, 2020 | $1.20 B |
24.50%
|
| Dec 31, 2019 | $0.96 B |
0.57%
|
| Dec 31, 2018 | $0.96 B |
-27.84%
|
| Dec 29, 2017 | $1.33 B |
-8.10%
|
| Dec 30, 2016 | $1.45 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Regeneron Pharmaceuticals
REGN
|
$60.99 B |
1.014 B
|
USA
|
 Amgen
AMGN
|
$158.77 B |
0.132 B
|
USA
|
 Biogen
BIIB
|
$17.12 B |
0.000 M
|
USA
|
 Gilead Sciences
GILD
|
$131.74 B |
-0.002 M
|
USA
|
 Vertex Pharmaceuticals
VRTX
|
$128.67 B |
-0.003 M
|
USA
|
 Moderna
MRNA
|
$10.14 B |
-0.001 M
|
USA
|
 BioNTech
BNTX
|
$23.80 B |
0.001 M
|
Germany
|
 Novavax
NVAX
|
$1.03 B |
0.000 M
|
USA
|
 Incyte
INCY
|
$11.31 B |
0.000 M
|
USA
|
 Alnylam Pharmaceuticals
ALNY
|
$29.89 B |
-0.001 M
|
USA
|
 bluebird bio
BLUE
|
$43.76 M |
0.000 M
|
USA
|
 CRISPR Therapeutics
CRSP
|
$3.34 B |
0.000 M
|
Switzerland
|
 Editas Medicine
EDIT
|
$0.11 B |
0.000 M
|
USA
|
 Intellia Therapeutics
NTLA
|
$0.76 B |
-0.000 M
|
USA
|
 Sangamo Therapeutics
SGMO
|
$0.17 B |
0.000 M
|
USA
|
| Market Cap | = | MRUS Stock Price | * | MRUS Shares Outstanding |
| = | $43.22 | * | 69.09 M | |
| = | $2.99 B |